帕金森病中的白质高信号、脑脊液淀粉样β蛋白与痴呆 - Suppr

White matter hyperintensities, cerebrospinal amyloid-β and dementia in Parkinson's disease.

作者信息

Compta Yaroslau, Buongiorno Mariateresa, Bargalló Núria, Valldeoriola Francesc, Muñoz Esteban, Tolosa Eduardo, Ríos José, Cámara Ana, Fernández Manel, Martí Maria J

机构信息

Parkinson disease & Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències (ICN), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain.

Magnetic Resonance Unit, Neurorradiology Section, Centre de Diagnòstic per la Imatge (CDI), IDIBAPS, Hospital Clínic, Barcelona, Catalonia, Spain.

出版信息

J Neurol Sci. 2016 Aug 15;367:284-90. doi: 10.1016/j.jns.2016.06.009. Epub 2016 Jun 11.

DOI:10.1016/j.jns.2016.06.009

PMID:27423605

Abstract

摘要

相似文献

White matter hyperintensities, cerebrospinal amyloid-β and dementia in Parkinson's disease.

J Neurol Sci. 2016 Aug 15;367:284-90. doi: 10.1016/j.jns.2016.06.009. Epub 2016 Jun 11.

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670. Epub 2011 Apr 5.

Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.

Dement Geriatr Cogn Disord. 2006;22(3):200-8. doi: 10.1159/000094871. Epub 2006 Aug 7.

Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.

Parkinsonism Relat Disord. 2015 Jul;21(7):758-64. doi: 10.1016/j.parkreldis.2015.04.027. Epub 2015 May 2.

Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Eur J Neurosci. 2016 Jan;43(1):3-16. doi: 10.1111/ejn.13056. Epub 2015 Oct 15.

Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.

J Neurol Sci. 2014 Aug 15;343(1-2):120-4. doi: 10.1016/j.jns.2014.05.052. Epub 2014 Jun 2.

Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.

J Parkinsons Dis. 2015;5(4):783-92. doi: 10.3233/JPD-150682.

Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson's disease.

J Neurol Sci. 2017 Feb 15;373:223-229. doi: 10.1016/j.jns.2016.12.064. Epub 2016 Dec 30.

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Arch Neurol. 2012 Nov;69(11):1445-52. doi: 10.1001/archneurol.2012.1654.

Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

Brain. 2015 Sep;138(Pt 9):2716-31. doi: 10.1093/brain/awv181. Epub 2015 Jun 30.

引用本文的文献

Reply: Reconsidering white matter vulnerability and biomarker interpretation across Lewy body dementia subtypes.

Alzheimers Dement. 2025 Aug;21(8):e70567. doi: 10.1002/alz.70567.

Reconsidering white matter vulnerability and biomarker interpretation across Lewy body dementia subtypes.

Alzheimers Dement. 2025 Aug;21(8):e70566. doi: 10.1002/alz.70566.

White matter hyperintensities and cholinergic degeneration as Lewy body disease.

Ann Clin Transl Neurol. 2025 Jan;12(1):97-109. doi: 10.1002/acn3.52257. Epub 2024 Dec 9.

The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy.

J Neurol. 2024 Oct;271(10):6866-6875. doi: 10.1007/s00415-024-12662-0. Epub 2024 Sep 2.

Altered sleep and neurovascular dysfunction in alpha-synucleinopathies: the perfect storm for glymphatic failure.

Front Aging Neurosci. 2023 Aug 24;15:1251755. doi: 10.3389/fnagi.2023.1251755. eCollection 2023.

Beta amyloid deposition and cognitive decline in Parkinson's disease: a study of the PPMI cohort.

Mol Brain. 2022 Sep 13;15(1):79. doi: 10.1186/s13041-022-00964-1.

Arterial Blood Pressure Variability and Other Vascular Factors Contribution to the Cognitive Decline in Parkinson's Disease.

Molecules. 2021 Mar 10;26(6):1523. doi: 10.3390/molecules26061523.

White Matter Lesions in Mild Cognitive Impairment and Idiopathic Parkinson's Disease: Multimodal Advanced MRI and Cognitive Associations.

J Neuroimaging. 2020 Nov;30(6):843-850. doi: 10.1111/jon.12778. Epub 2020 Sep 16.

Confining the Concept of Vascular Depression to Late-Onset Depression: A Meta-Analysis of MRI-Defined Hyperintensity Burden in Major Depressive Disorder and Bipolar Disorder.

Front Psychol. 2019 May 31;10:1241. doi: 10.3389/fpsyg.2019.01241. eCollection 2019.

Amyloid-β and Parkinson's disease.

J Neurol. 2019 Nov;266(11):2605-2619. doi: 10.1007/s00415-018-9100-8. Epub 2018 Oct 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

White matter hyperintensities, cerebrospinal amyloid-β and dementia in Parkinson's disease.

作者信息

Compta Yaroslau, Buongiorno Mariateresa, Bargalló Núria, Valldeoriola Francesc, Muñoz Esteban, Tolosa Eduardo, Ríos José, Cámara Ana, Fernández Manel, Martí Maria J

机构信息

Magnetic Resonance Unit, Neurorradiology Section, Centre de Diagnòstic per la Imatge (CDI), IDIBAPS, Hospital Clínic, Barcelona, Catalonia, Spain.

出版信息

J Neurol Sci. 2016 Aug 15;367:284-90. doi: 10.1016/j.jns.2016.06.009. Epub 2016 Jun 11.

DOI:10.1016/j.jns.2016.06.009

PMID:27423605

Abstract

摘要

相似文献

White matter hyperintensities, cerebrospinal amyloid-β and dementia in Parkinson's disease.

J Neurol Sci. 2016 Aug 15;367:284-90. doi: 10.1016/j.jns.2016.06.009. Epub 2016 Jun 11.

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670. Epub 2011 Apr 5.

Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.

Dement Geriatr Cogn Disord. 2006;22(3):200-8. doi: 10.1159/000094871. Epub 2006 Aug 7.

Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.

Parkinsonism Relat Disord. 2015 Jul;21(7):758-64. doi: 10.1016/j.parkreldis.2015.04.027. Epub 2015 May 2.

Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Eur J Neurosci. 2016 Jan;43(1):3-16. doi: 10.1111/ejn.13056. Epub 2015 Oct 15.

Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.

J Neurol Sci. 2014 Aug 15;343(1-2):120-4. doi: 10.1016/j.jns.2014.05.052. Epub 2014 Jun 2.

Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.

J Parkinsons Dis. 2015;5(4):783-92. doi: 10.3233/JPD-150682.

Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson's disease.

J Neurol Sci. 2017 Feb 15;373:223-229. doi: 10.1016/j.jns.2016.12.064. Epub 2016 Dec 30.

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Arch Neurol. 2012 Nov;69(11):1445-52. doi: 10.1001/archneurol.2012.1654.

Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

Brain. 2015 Sep;138(Pt 9):2716-31. doi: 10.1093/brain/awv181. Epub 2015 Jun 30.

引用本文的文献

Reply: Reconsidering white matter vulnerability and biomarker interpretation across Lewy body dementia subtypes.

Alzheimers Dement. 2025 Aug;21(8):e70567. doi: 10.1002/alz.70567.

Reconsidering white matter vulnerability and biomarker interpretation across Lewy body dementia subtypes.

Alzheimers Dement. 2025 Aug;21(8):e70566. doi: 10.1002/alz.70566.

White matter hyperintensities and cholinergic degeneration as Lewy body disease.

Ann Clin Transl Neurol. 2025 Jan;12(1):97-109. doi: 10.1002/acn3.52257. Epub 2024 Dec 9.

The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy.

J Neurol. 2024 Oct;271(10):6866-6875. doi: 10.1007/s00415-024-12662-0. Epub 2024 Sep 2.

Altered sleep and neurovascular dysfunction in alpha-synucleinopathies: the perfect storm for glymphatic failure.

Front Aging Neurosci. 2023 Aug 24;15:1251755. doi: 10.3389/fnagi.2023.1251755. eCollection 2023.

Beta amyloid deposition and cognitive decline in Parkinson's disease: a study of the PPMI cohort.

Mol Brain. 2022 Sep 13;15(1):79. doi: 10.1186/s13041-022-00964-1.

Arterial Blood Pressure Variability and Other Vascular Factors Contribution to the Cognitive Decline in Parkinson's Disease.

Molecules. 2021 Mar 10;26(6):1523. doi: 10.3390/molecules26061523.

White Matter Lesions in Mild Cognitive Impairment and Idiopathic Parkinson's Disease: Multimodal Advanced MRI and Cognitive Associations.

J Neuroimaging. 2020 Nov;30(6):843-850. doi: 10.1111/jon.12778. Epub 2020 Sep 16.

Confining the Concept of Vascular Depression to Late-Onset Depression: A Meta-Analysis of MRI-Defined Hyperintensity Burden in Major Depressive Disorder and Bipolar Disorder.

Front Psychol. 2019 May 31;10:1241. doi: 10.3389/fpsyg.2019.01241. eCollection 2019.

Amyloid-β and Parkinson's disease.

J Neurol. 2019 Nov;266(11):2605-2619. doi: 10.1007/s00415-018-9100-8. Epub 2018 Oct 30.

White matter hyperintensities, cerebrospinal amyloid-β and dementia in Parkinson's disease.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

White matter hyperintensities, cerebrospinal amyloid-β and dementia in Parkinson's disease.

作者信息

机构信息

出版信息

相似文献

引用本文的文献